Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 17;11(15):2934–2943. doi: 10.1002/cam4.4659

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Promising objective response rate (ORR) for combinatory immune checkpoint inhibitor (ICI)/interleukin (IL) therapy in patients with cancer. The combination of programmed death‐1 receptor (PD‐1) inhibitors with IL12 plasmid and PEGylated recombinant IL‐10 (also called pegilodecakin) renders noticeable ORR in cancer patients. ORR is also significant for the IL‐15 superagonist ALT‐803. The most considerable objective response is for the IL‐2 agonist bempegaldesleukin (also called NKTR‐214), which is designed preferentially for CD122 (IL‐2β receptor)